Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological f...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 70; no. 3; pp. 530 - 536 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd and European League Against Rheumatism
01.03.2011
BMJ Publishing Group Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. |
---|---|
AbstractList | Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc.
Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality.
Anti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists.
Functional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc.BACKGROUNDSystemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc.Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality.METHODSSerum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality.Anti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists.RESULTSAnti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists.Functional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.CONCLUSIONSFunctional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. BACKGROUND: Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. METHODS: Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. RESULTS: Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor beta gene expression in endothelial cells which could be blocked with specific receptor antagonists. CONCLUSIONS: Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1 R) and endothelin-1 type A receptor (ETA R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1 R and anti-ETA R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1 R and ETA R is common in patients with SSc. AT1 R and ETA R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression. |
Author | Becker, Mike Luft, Friedrich C Kill, Angela Philippe, Aurélie Catar, Rusan Näther, Melanie Hegner, Björn Burmester, Gerd R Lukitsch, Ivo van Laar, Jacob M Slowinski, Torsten Riemekasten, Gabriela Matucci-Cerinic, Marco Müller, Dominik N Czirják, László Heidecke, Harald Dragun, Duska |
Author_xml | – sequence: 1 givenname: Gabriela surname: Riemekasten fullname: Riemekasten, Gabriela email: duska.dragun@charite.de organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany – sequence: 2 givenname: Aurélie surname: Philippe fullname: Philippe, Aurélie email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany – sequence: 3 givenname: Melanie surname: Näther fullname: Näther, Melanie email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany – sequence: 4 givenname: Torsten surname: Slowinski fullname: Slowinski, Torsten email: duska.dragun@charite.de organization: Department of Nephrology, CCM, Charité University Hospital, Berlin, Germany – sequence: 5 givenname: Dominik N surname: Müller fullname: Müller, Dominik N email: duska.dragun@charite.de organization: Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany – sequence: 6 givenname: Harald surname: Heidecke fullname: Heidecke, Harald email: duska.dragun@charite.de organization: CellTrend GmbH Luckenwalde, Luckenwalde, Germany – sequence: 7 givenname: Marco surname: Matucci-Cerinic fullname: Matucci-Cerinic, Marco email: duska.dragun@charite.de organization: Department of Rheumatology, University of Florence, Florence, Italy – sequence: 8 givenname: László surname: Czirják fullname: Czirják, László email: duska.dragun@charite.de organization: Department of Rheumatology and Immunology, University of Pecs, Pecs, Hungary – sequence: 9 givenname: Ivo surname: Lukitsch fullname: Lukitsch, Ivo email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany – sequence: 10 givenname: Mike surname: Becker fullname: Becker, Mike email: duska.dragun@charite.de organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany – sequence: 11 givenname: Angela surname: Kill fullname: Kill, Angela email: duska.dragun@charite.de organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany – sequence: 12 givenname: Jacob M surname: van Laar fullname: van Laar, Jacob M email: duska.dragun@charite.de organization: Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK – sequence: 13 givenname: Rusan surname: Catar fullname: Catar, Rusan email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany – sequence: 14 givenname: Friedrich C surname: Luft fullname: Luft, Friedrich C email: duska.dragun@charite.de organization: Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany – sequence: 15 givenname: Gerd R surname: Burmester fullname: Burmester, Gerd R email: duska.dragun@charite.de organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany – sequence: 16 givenname: Björn surname: Hegner fullname: Hegner, Björn email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany – sequence: 17 givenname: Duska surname: Dragun fullname: Dragun, Duska email: duska.dragun@charite.de organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23877242$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21081526$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1rFTEUhoNU7G117U4GRArCtPmYfMyyXD9aKbpQC3YTkkxGcp1Jrknm0v57M8ytQkG6yjnwvIfwPkfgwAdvAXiJ4ClChJ2p2J1iOG-Eco6fgBVqmKgxZPAArCCEpG5axg_BUUqbskKBxDNwiFEZKGYr8OPS78Kws6P1uQp91U_eZBe8Gio15aB8djp0zqZK_VTOp1ztVDLToGIVrbHbHGKqnK_SXcp2dKZKZrAxJJeeg6e9GpJ9sX-PwfcP77-tL-qrLx8v1-dXtaaY5hphrqxuGyqINhozziDSxHDYUMqEQqjTuuWm6RSmxlKqVS-0sBppxKglmByDk-XuNobfk01Zji4ZOwzK2zAl2UKOaMPbx0nRtA1uIYaFfP2A3IQpllKSRJxzwSDhvFCv9tSkR9vJbXSjinfyvt0CvNkDpTM19FF549I_jojirJk_RhfOlOZStL00LqtZQ47KDRJBOduWxbacbcvFdsmdPcjdn_5_ol4Srui6_Yur-EsyTjiVn6_X8hrd3Lwjn77Ki8K_XXg9bh49_getwMfw |
CODEN | ARDIAO |
CitedBy_id | crossref_primary_10_1097_TP_0b013e318234b337 crossref_primary_10_3389_fimmu_2024_1491324 crossref_primary_10_1016_j_atherosclerosissup_2012_10_034 crossref_primary_10_3390_biomedicines10020502 crossref_primary_10_1136_annrheumdis_2011_200195 crossref_primary_10_1007_s11926_015_0505_4 crossref_primary_10_1038_s41573_025_01158_9 crossref_primary_10_3389_fimmu_2021_684142 crossref_primary_10_1002_jmv_28864 crossref_primary_10_1111_bph_14213 crossref_primary_10_3389_fimmu_2021_677970 crossref_primary_10_1378_chest_12_2396 crossref_primary_10_1136_postgradmedj_2011_130364 crossref_primary_10_1186_ar4457 crossref_primary_10_1136_annrheumdis_2019_215341 crossref_primary_10_1016_j_atherosclerosis_2023_06_970 crossref_primary_10_1038_s41467_018_07598_9 crossref_primary_10_1111_aji_12072 crossref_primary_10_12688_f1000research_10022_1 crossref_primary_10_1093_abbs_gmr096 crossref_primary_10_1007_s00393_011_0914_3 crossref_primary_10_23736_S0393_3660_23_05188_4 crossref_primary_10_1016_j_autrev_2017_07_019 crossref_primary_10_3389_fimmu_2020_564526 crossref_primary_10_1016_j_rdc_2015_04_002 crossref_primary_10_1111_ajt_15571 crossref_primary_10_1161_HYPERTENSIONAHA_111_171348 crossref_primary_10_1016_j_semarthrit_2021_01_001 crossref_primary_10_1016_j_autrev_2022_103230 crossref_primary_10_1016_j_xkme_2023_100753 crossref_primary_10_1097_BOR_0b013e3283524b9a crossref_primary_10_1016_j_autrev_2022_103231 crossref_primary_10_3899_jrheum_150061 crossref_primary_10_1136_ard_2023_224092 crossref_primary_10_1097_TP_0000000000001231 crossref_primary_10_1016_j_kint_2019_01_030 crossref_primary_10_1016_j_autrev_2019_102371 crossref_primary_10_1111_1756_185X_13001 crossref_primary_10_1186_ar4230 crossref_primary_10_3390_ijms23020927 crossref_primary_10_1007_s11926_012_0296_9 crossref_primary_10_1097_TP_0000000000001904 crossref_primary_10_1007_s00467_021_04969_1 crossref_primary_10_4049_jimmunol_1502190 crossref_primary_10_1016_j_autrev_2023_103386 crossref_primary_10_1016_j_transproceed_2021_01_013 crossref_primary_10_1136_rmdopen_2023_003626 crossref_primary_10_1371_journal_pone_0210023 crossref_primary_10_1016_j_clindermatol_2018_04_008 crossref_primary_10_1111_aji_12097 crossref_primary_10_1097_BOR_0000000000000959 crossref_primary_10_3389_fimmu_2018_00428 crossref_primary_10_3390_ijms24086960 crossref_primary_10_1038_srep23508 crossref_primary_10_1093_rheumatology_keaa747 crossref_primary_10_1016_j_explore_2013_10_001 crossref_primary_10_1186_s13075_022_02896_6 crossref_primary_10_1007_s10067_016_3504_6 crossref_primary_10_1007_s00281_015_0513_5 crossref_primary_10_1097_TP_0000000000003797 crossref_primary_10_1136_rmdopen_2024_004290 crossref_primary_10_1007_s40618_024_02412_4 crossref_primary_10_3389_fendo_2022_880002 crossref_primary_10_1186_s13075_018_1545_8 crossref_primary_10_1111_tri_13009 crossref_primary_10_1080_08916934_2021_1916915 crossref_primary_10_3899_jrheum_150474 crossref_primary_10_1007_s00393_024_01539_2 crossref_primary_10_1007_s00018_014_1713_1 crossref_primary_10_1016_j_autrev_2018_08_003 crossref_primary_10_1111_ajt_14053 crossref_primary_10_1093_rheumatology_keac594 crossref_primary_10_1093_rheumatology_ker414 crossref_primary_10_1097_TP_0000000000000179 crossref_primary_10_1136_annrheumdis_2020_217166 crossref_primary_10_3390_jpm11111207 crossref_primary_10_2169_internalmedicine_1423_18 crossref_primary_10_1016_j_clim_2025_110454 crossref_primary_10_1007_s00108_019_00699_7 crossref_primary_10_1038_nrrheum_2010_218 crossref_primary_10_1161_HYPERTENSIONAHA_119_12105 crossref_primary_10_1371_journal_pone_0100035 crossref_primary_10_1016_j_kint_2016_03_019 crossref_primary_10_1371_journal_pone_0129910 crossref_primary_10_1124_jpet_114_221606 crossref_primary_10_1586_edm_13_8 crossref_primary_10_3390_ijms23010244 crossref_primary_10_1016_j_freeradbiomed_2018_05_085 crossref_primary_10_2174_011573398X268623231212180622 crossref_primary_10_2174_0929867325666180201095743 crossref_primary_10_1093_ajh_hpu142 crossref_primary_10_1111_ajt_13866 crossref_primary_10_1097_TP_0000000000000182 crossref_primary_10_6064_2012_215308 crossref_primary_10_47184_ti_2021_01_04 crossref_primary_10_1164_rccm_201105_0927OC crossref_primary_10_1016_j_transproceed_2018_05_022 crossref_primary_10_31083_j_fbs1504016 crossref_primary_10_1016_j_jcf_2014_07_007 crossref_primary_10_1161_JAHA_115_002323 crossref_primary_10_1002_art_39212 crossref_primary_10_1016_j_autrev_2015_10_005 crossref_primary_10_1586_ers_11_18 crossref_primary_10_1186_1750_1326_9_49 crossref_primary_10_3390_ijms25042299 crossref_primary_10_1111_tri_12282 crossref_primary_10_1177_23971983231168193 crossref_primary_10_1093_rheumatology_keu463 crossref_primary_10_1016_j_jaut_2021_102683 crossref_primary_10_3389_fimmu_2017_00075 crossref_primary_10_3390_medicina60010170 crossref_primary_10_5301_jsrd_5000249 crossref_primary_10_3109_10641955_2015_1051227 crossref_primary_10_1007_s40674_016_0050_y crossref_primary_10_5301_jsrd_5000241 crossref_primary_10_3390_ijms222111793 crossref_primary_10_1177_2397198319870667 crossref_primary_10_3389_fimmu_2017_00603 crossref_primary_10_1097_TP_0000000000001853 crossref_primary_10_1080_1744666X_2019_1614915 crossref_primary_10_1016_j_humimm_2019_04_007 crossref_primary_10_1016_j_humimm_2019_04_008 crossref_primary_10_1016_j_ekir_2020_09_004 crossref_primary_10_1007_s00281_014_0425_9 crossref_primary_10_1016_j_trre_2017_08_005 crossref_primary_10_1586_eci_11_56 crossref_primary_10_1016_j_trre_2016_06_001 crossref_primary_10_1097_01_TP_0000436927_08026_a8 crossref_primary_10_1097_MOT_0b013e328355f12b crossref_primary_10_1016_j_jri_2022_103777 crossref_primary_10_1016_j_kint_2021_04_044 crossref_primary_10_1124_pr_114_010454 crossref_primary_10_3390_diagnostics11050911 crossref_primary_10_1093_rheumatology_keac549 crossref_primary_10_1183_13993003_01949_2023 crossref_primary_10_1038_s41467_022_28905_5 crossref_primary_10_1111_bjd_17886 crossref_primary_10_3390_ijms21041382 crossref_primary_10_1097_BOR_0000000000000215 crossref_primary_10_1002_art_43099 crossref_primary_10_1016_j_imlet_2017_10_007 crossref_primary_10_1016_j_autrev_2014_12_001 crossref_primary_10_1016_j_jaad_2022_06_1199 crossref_primary_10_1016_j_autrev_2023_103310 crossref_primary_10_1038_nrrheum_2013_46 crossref_primary_10_1177_1759720X221109404 crossref_primary_10_1097_FJC_0000000000001264 crossref_primary_10_1097_MOT_0b013e3283636e55 crossref_primary_10_3390_jcm9092687 crossref_primary_10_1007_s00109_014_1190_x crossref_primary_10_3389_fimmu_2018_02457 crossref_primary_10_1111_tri_12371 crossref_primary_10_1186_s40729_021_00398_9 crossref_primary_10_1007_s12016_022_08945_x crossref_primary_10_1055_a_1120_8647 crossref_primary_10_1016_j_berh_2012_01_011 crossref_primary_10_1093_icvts_ivv344 crossref_primary_10_1007_s11936_021_00947_w crossref_primary_10_1002_art_37873 crossref_primary_10_1016_j_humimm_2019_04_012 crossref_primary_10_3389_fimmu_2023_1213804 crossref_primary_10_1038_s41584_019_0322_7 crossref_primary_10_1161_JAHA_123_032441 crossref_primary_10_1080_09273948_2024_2308030 crossref_primary_10_1016_j_jacc_2019_02_067 crossref_primary_10_1016_j_jacc_2019_02_064 crossref_primary_10_3390_jcm13247752 crossref_primary_10_3389_fimmu_2022_895501 crossref_primary_10_3389_fimmu_2022_954007 crossref_primary_10_1007_s40674_021_00171_4 crossref_primary_10_1016_j_rdc_2022_08_002 crossref_primary_10_1186_ar4503 crossref_primary_10_1016_j_molimm_2020_12_027 crossref_primary_10_1586_1744666X_2016_1115717 crossref_primary_10_3390_biomedicines10092150 crossref_primary_10_1002_art_39865 crossref_primary_10_1111_ajt_12397 crossref_primary_10_1056_NEJMc1207233 crossref_primary_10_1016_j_niox_2019_02_006 crossref_primary_10_3109_07853890_2011_653396 crossref_primary_10_1136_annrheumdis_2021_222088 crossref_primary_10_3390_ijms24044178 crossref_primary_10_1016_j_humimm_2012_07_010 crossref_primary_10_1177_23971983231175213 crossref_primary_10_1016_j_tips_2020_11_013 crossref_primary_10_21693_1933_088X_16_2_61 crossref_primary_10_1002_jcp_31266 crossref_primary_10_1186_s12920_019_0632_2 crossref_primary_10_1016_j_autrev_2018_06_009 crossref_primary_10_1016_j_autrev_2012_05_011 crossref_primary_10_1097_MAJ_0b013e3182a55d24 crossref_primary_10_1111_exd_14159 crossref_primary_10_1164_rccm_201403_0442OC crossref_primary_10_1007_s10067_019_04745_5 crossref_primary_10_3390_biom14091054 crossref_primary_10_5664_jcsm_8036 crossref_primary_10_1016_j_revmed_2016_02_016 crossref_primary_10_1164_rccm_201412_2322LE crossref_primary_10_1038_nrrheum_2014_195 crossref_primary_10_3390_jcm11030833 crossref_primary_10_2147_CCID_S409490 crossref_primary_10_2217_ijr_13_65 crossref_primary_10_1038_nrrheum_2017_134 crossref_primary_10_1515_JLM_2011_051 crossref_primary_10_1016_j_autrev_2016_03_005 crossref_primary_10_1097_BOR_0000000000001035 crossref_primary_10_1161_CIRCRESAHA_113_300752 crossref_primary_10_3389_fimmu_2021_786039 crossref_primary_10_1016_j_jid_2017_03_032 crossref_primary_10_1155_ijr_1682081 crossref_primary_10_3389_fimmu_2022_1045523 crossref_primary_10_1152_physiol_00014_2013 crossref_primary_10_1053_j_ajkd_2015_03_033 crossref_primary_10_1055_a_2322_2289 crossref_primary_10_1097_TP_0b013e3182692ad2 crossref_primary_10_3389_fmed_2015_00013 crossref_primary_10_3389_fimmu_2022_925741 crossref_primary_10_1016_j_semarthrit_2022_152136 crossref_primary_10_3390_ijms23073984 crossref_primary_10_1007_s00281_015_0506_4 crossref_primary_10_3390_antib12010003 crossref_primary_10_1016_j_lpm_2014_06_007 crossref_primary_10_1111_micc_12440 crossref_primary_10_1007_s00296_016_3639_4 crossref_primary_10_1016_j_autrev_2024_103514 crossref_primary_10_1183_20734735_0183_2023 |
Cites_doi | 10.1172/JCI31139 10.1136/ard.2005.048967 10.4065/70.11.1068 10.1126/science.1165480 10.1016/S0889-857X(05)70295-7 10.1136/ard.61.6.554 10.1002/art.24381 10.1136/ard.2007.079921 10.1136/ard.2006.066068 10.1016/S0031-6997(24)01458-3 10.1002/art.20676 10.1002/art.1780310302 10.1172/JCI26031 10.1002/1529-0131(200107)44:7<1484::AID-ART269>3.0.CO;2-Q 10.1002/art.11073 10.1161/HYPERTENSIONAHA.107.091322 10.1073/pnas.1834556100 10.1136/ard.2006.062901 10.1002/art.24365 10.7326/0003-4819-107-2-216 10.1172/JCI4106 10.1056/NEJMoa052955 10.1056/NEJMoa035717 10.1210/en.2003-0673 10.1002/art.11364 10.1146/annurev.pharmtox.47.120505.105134 10.1002/art.24364 10.1002/art.11113 |
ContentType | Journal Article |
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 INIST-CNRS Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2015 INIST-CNRS – notice: Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9- K9. LK8 M0R M0S M1P M2P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7T5 H94 |
DOI | 10.1136/ard.2010.135772 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (ProQuest) Proquest Central Journals Natural Science Collection (ProQuest) BMJ Journals ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Proquest SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: Proquest Central Journals url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 536 |
ExternalDocumentID | 4008500991 21081526 23877242 10_1136_ard_2010_135772 ark_67375_NVC_V1ZZD3JS_H annrheumdis |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 0R~ 3V. BSCLL FRP IGG RHF AAFWJ AALRI AAYXX CITATION PHGZM IQODW PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM PKN 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 7T5 H94 |
ID | FETCH-LOGICAL-b525t-127aeb94583bcb267601b3c7045568a11dbb97c4da25ce55baf8b8eb1b165e323 |
IEDL.DBID | 7X7 |
ISSN | 0003-4967 1468-2060 |
IngestDate | Fri Jul 11 12:27:31 EDT 2025 Tue Aug 05 10:39:59 EDT 2025 Fri Jul 25 11:17:46 EDT 2025 Sat Feb 15 01:21:14 EST 2025 Mon Jul 21 09:18:22 EDT 2025 Thu Apr 24 22:52:56 EDT 2025 Tue Jul 01 04:23:20 EDT 2025 Wed Oct 30 10:01:21 EDT 2024 Thu Apr 24 23:06:54 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Autoimmunity Immunopathology Connective tissue disease Skin disease Blood vessel Systemic disease Rheumatology Autoantibody Autoimmune disease Scleroderma |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b525t-127aeb94583bcb267601b3c7045568a11dbb97c4da25ce55baf8b8eb1b165e323 |
Notes | ark:/67375/NVC-V1ZZD3JS-H href:annrheumdis-70-530.pdf ArticleID:annrheumdis135772 PMID:21081526 local:annrheumdis;70/3/530 EUSTAR investigators istex:EB5D4917B5AA995DD0932E5FB9F057BE8ECEB24D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 21081526 |
PQID | 1777860377 |
PQPubID | 2041045 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_907154792 proquest_miscellaneous_849429020 proquest_journals_1777860377 pubmed_primary_21081526 pascalfrancis_primary_23877242 crossref_citationtrail_10_1136_ard_2010_135772 crossref_primary_10_1136_ard_2010_135772 istex_primary_ark_67375_NVC_V1ZZD3JS_H bmj_primary_10_1136_ard_2010_135772 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-03-01 |
PublicationDateYYYYMMDD | 2011-03-01 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England – name: Kidlington |
PublicationTitle | Annals of the rheumatic diseases |
PublicationTitleAlternate | Ann Rheum Dis |
PublicationYear | 2011 |
Publisher | BMJ Publishing Group Ltd and European League Against Rheumatism BMJ Publishing Group Elsevier Limited |
Publisher_xml | – name: BMJ Publishing Group Ltd and European League Against Rheumatism – name: BMJ Publishing Group – name: Elsevier Limited |
References | Rich, Dantzker, Ayres 1987; 107 Schneider, Boesen, Pollock 2007; 47 Davies, Ando, Lin 2005; 115 Steen, Medsger 2007; 66 Wallukat, Homuth, Fischer 1999; 103 Denton, Humbert, Rubin 2006; 65 Peterson, Nelson, Su 1995; 70 Bostrom, Yu, Kan 2009; 323 LeRoy, Medsger 1992; 10 Korn, Mayes, Matucci Cerinic 2004; 50 Vitali, Bombardieri, Jonsson 2002; 61 LeRoy 1996; 22 Mayes, Lacey, Beebe-Dimmer 2003; 48 Xia, Ramin, Kellems 2007; 50 de Gasparo, Catt, Inagami 2000; 52 Min, Cui, Yahata 2004; 145 Kawaguchi, Takagi, Hara 2004; 50 Denton, Pope, Peter 2008; 67 Malcarne, Hansdottir, McKinney 2007; 34 Reveille, Solomon 2003; 49 Arnett, Edworthy, Bloch 1988; 31 Baroni, Santillo, Bevilacqua 2006; 354 Varga, Abraham 2007; 117 Walker, Tyndall, Czirják 2007; 66 Dragun, Müller, Bräsen 2005; 352 Praprotnik, Blank, Meroni 2001; 44 LeRoy, Black, Fleischmajer 1988; 15 Classen, Henrohn, Rorsman 2009; 60 Yamane, Miyauchi, Suzuki 1992; 19 Dragun, Distler, Riemekasten 2009; 60 Wei, Ahn, Shenoy 2003; 100 Loizos, Lariccia, Weiner 2009; 60 Mayes (10.1136/ard.2010.135772_bib2) 2003; 48 LeRoy (10.1136/ard.2010.135772_bib20) 1992; 10 Wallukat (10.1136/ard.2010.135772_bib14) 1999; 103 Denton (10.1136/ard.2010.135772_bib5) 2008; 67 Bostrom (10.1136/ard.2010.135772_bib27) 2009; 323 Malcarne (10.1136/ard.2010.135772_bib4) 2007; 34 Schneider (10.1136/ard.2010.135772_bib12) 2007; 47 Xia (10.1136/ard.2010.135772_bib15) 2007; 50 Korn (10.1136/ard.2010.135772_bib8) 2004; 50 Classen (10.1136/ard.2010.135772_bib24) 2009; 60 Kawaguchi (10.1136/ard.2010.135772_bib9) 2004; 50 Rich (10.1136/ard.2010.135772_bib21) 1987; 107 Reveille (10.1136/ard.2010.135772_bib29) 2003; 49 Min (10.1136/ard.2010.135772_bib32) 2004; 145 LeRoy (10.1136/ard.2010.135772_bib16) 1988; 15 Walker (10.1136/ard.2010.135772_bib17) 2007; 66 Vitali (10.1136/ard.2010.135772_bib22) 2002; 61 Dragun (10.1136/ard.2010.135772_bib13) 2005; 352 LeRoy (10.1136/ard.2010.135772_bib3) 1996; 22 Steen (10.1136/ard.2010.135772_bib6) 2007; 66 Praprotnik (10.1136/ard.2010.135772_bib28) 2001; 44 Davies (10.1136/ard.2010.135772_bib31) 2005; 115 Denton (10.1136/ard.2010.135772_bib7) 2006; 65 Loizos (10.1136/ard.2010.135772_bib25) 2009; 60 Peterson (10.1136/ard.2010.135772_bib19) 1995; 70 Yamane (10.1136/ard.2010.135772_bib10) 1992; 19 Dragun (10.1136/ard.2010.135772_bib26) 2009; 60 Baroni (10.1136/ard.2010.135772_bib23) 2006; 354 Arnett (10.1136/ard.2010.135772_bib18) 1988; 31 Varga (10.1136/ard.2010.135772_bib1) 2007; 117 de Gasparo (10.1136/ard.2010.135772_bib11) 2000; 52 Wei (10.1136/ard.2010.135772_bib30) 2003; 100 21374902 - Nat Rev Rheumatol. 2011 Feb;7(2):71. doi: 10.1038/nrrheum.2010.218. |
References_xml | – volume: 50 start-page: 3985 year: 2004 article-title: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist publication-title: Arthritis Rheum – volume: 354 start-page: 2667 year: 2006 article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis publication-title: N Engl J Med – volume: 50 start-page: 269 year: 2007 article-title: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia publication-title: Hypertension – volume: 115 start-page: 1972 year: 2005 article-title: Thyrotropin receptor-associated diseases: from adenomata to Graves disease publication-title: J Clin Invest – volume: 70 start-page: 1068 year: 1995 article-title: Classification of morphea (localized scleroderma) publication-title: Mayo Clin Proc – volume: 61 start-page: 554 year: 2002 article-title: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group publication-title: Ann Rheum Dis – volume: 60 start-page: 907 year: 2009 article-title: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology publication-title: Arthritis Rheum – volume: 10 start-page: 485 year: 1992 article-title: Raynaud's phenomenon: a proposal for classification publication-title: Clin Exp Rheumatol – volume: 65 start-page: 1336 year: 2006 article-title: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions publication-title: Ann Rheum Dis – volume: 60 start-page: 1137 year: 2009 article-title: Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis publication-title: Arthritis Rheum – volume: 66 start-page: 940 year: 2007 article-title: Changes in causes of death in systemic sclerosis, 1972–2002 publication-title: Ann Rheum Dis – volume: 52 start-page: 415 year: 2000 article-title: International union of pharmacology. XXIII. The angiotensin II receptors publication-title: Pharmacol Rev – volume: 15 start-page: 202 year: 1988 article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis publication-title: J Rheumatol – volume: 50 start-page: 216 year: 2004 article-title: Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors publication-title: Arthritis Rheum – volume: 48 start-page: 2246 year: 2003 article-title: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population publication-title: Arthritis Rheum – volume: 19 start-page: 1566 year: 1992 article-title: Significance of plasma endothelin-1 levels in patients with systemic sclerosis publication-title: J Rheumatol – volume: 107 start-page: 216 year: 1987 article-title: Primary pulmonary hypertension. A national prospective study publication-title: Ann Intern Med – volume: 323 start-page: 1610 year: 2009 article-title: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site publication-title: Science – volume: 100 start-page: 10782 year: 2003 article-title: Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 publication-title: Proc Natl Acad Sci USA – volume: 352 start-page: 558 year: 2005 article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection publication-title: N Engl J Med – volume: 103 start-page: 945 year: 1999 article-title: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor publication-title: J Clin Invest – volume: 44 start-page: 1484 year: 2001 article-title: Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications publication-title: Arthritis Rheum – volume: 145 start-page: 253 year: 2004 article-title: Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes publication-title: Endocrinology – volume: 31 start-page: 315 year: 1988 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum – volume: 117 start-page: 557 year: 2007 article-title: Systemic sclerosis: a prototypic multisystem fibrotic disorder publication-title: J Clin Invest – volume: 34 start-page: 359 year: 2007 article-title: Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis publication-title: J Rheumatol – volume: 47 start-page: 731 year: 2007 article-title: Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease publication-title: Annu Rev Pharmacol Toxicol – volume: 67 start-page: 1222 year: 2008 article-title: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases publication-title: Ann Rheum Dis – volume: 22 start-page: 675 year: 1996 article-title: Systemic sclerosis. A vascular perspective publication-title: Rheum Dis Clin North Am – volume: 66 start-page: 754 year: 2007 article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database publication-title: Ann Rheum Dis – volume: 49 start-page: 399 year: 2003 article-title: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies publication-title: Arthritis Rheum – volume: 60 start-page: 1145 year: 2009 article-title: Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera publication-title: Arthritis Rheum – volume: 117 start-page: 557 year: 2007 ident: 10.1136/ard.2010.135772_bib1 article-title: Systemic sclerosis: a prototypic multisystem fibrotic disorder publication-title: J Clin Invest doi: 10.1172/JCI31139 – volume: 65 start-page: 1336 year: 2006 ident: 10.1136/ard.2010.135772_bib7 article-title: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions publication-title: Ann Rheum Dis doi: 10.1136/ard.2005.048967 – volume: 10 start-page: 485 year: 1992 ident: 10.1136/ard.2010.135772_bib20 article-title: Raynaud's phenomenon: a proposal for classification publication-title: Clin Exp Rheumatol – volume: 70 start-page: 1068 year: 1995 ident: 10.1136/ard.2010.135772_bib19 article-title: Classification of morphea (localized scleroderma) publication-title: Mayo Clin Proc doi: 10.4065/70.11.1068 – volume: 323 start-page: 1610 year: 2009 ident: 10.1136/ard.2010.135772_bib27 article-title: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site publication-title: Science doi: 10.1126/science.1165480 – volume: 22 start-page: 675 year: 1996 ident: 10.1136/ard.2010.135772_bib3 article-title: Systemic sclerosis. A vascular perspective publication-title: Rheum Dis Clin North Am doi: 10.1016/S0889-857X(05)70295-7 – volume: 61 start-page: 554 year: 2002 ident: 10.1136/ard.2010.135772_bib22 article-title: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group publication-title: Ann Rheum Dis doi: 10.1136/ard.61.6.554 – volume: 60 start-page: 1137 year: 2009 ident: 10.1136/ard.2010.135772_bib24 article-title: Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis publication-title: Arthritis Rheum doi: 10.1002/art.24381 – volume: 67 start-page: 1222 year: 2008 ident: 10.1136/ard.2010.135772_bib5 article-title: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.079921 – volume: 66 start-page: 940 year: 2007 ident: 10.1136/ard.2010.135772_bib6 article-title: Changes in causes of death in systemic sclerosis, 1972–2002 publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.066068 – volume: 52 start-page: 415 year: 2000 ident: 10.1136/ard.2010.135772_bib11 article-title: International union of pharmacology. XXIII. The angiotensin II receptors publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(24)01458-3 – volume: 50 start-page: 3985 year: 2004 ident: 10.1136/ard.2010.135772_bib8 article-title: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist publication-title: Arthritis Rheum doi: 10.1002/art.20676 – volume: 34 start-page: 359 year: 2007 ident: 10.1136/ard.2010.135772_bib4 article-title: Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis publication-title: J Rheumatol – volume: 31 start-page: 315 year: 1988 ident: 10.1136/ard.2010.135772_bib18 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.1780310302 – volume: 115 start-page: 1972 year: 2005 ident: 10.1136/ard.2010.135772_bib31 article-title: Thyrotropin receptor-associated diseases: from adenomata to Graves disease publication-title: J Clin Invest doi: 10.1172/JCI26031 – volume: 44 start-page: 1484 year: 2001 ident: 10.1136/ard.2010.135772_bib28 article-title: Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200107)44:7<1484::AID-ART269>3.0.CO;2-Q – volume: 48 start-page: 2246 year: 2003 ident: 10.1136/ard.2010.135772_bib2 article-title: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population publication-title: Arthritis Rheum doi: 10.1002/art.11073 – volume: 15 start-page: 202 year: 1988 ident: 10.1136/ard.2010.135772_bib16 article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis publication-title: J Rheumatol – volume: 50 start-page: 269 year: 2007 ident: 10.1136/ard.2010.135772_bib15 article-title: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.107.091322 – volume: 100 start-page: 10782 year: 2003 ident: 10.1136/ard.2010.135772_bib30 article-title: Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1834556100 – volume: 66 start-page: 754 year: 2007 ident: 10.1136/ard.2010.135772_bib17 article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.062901 – volume: 60 start-page: 1145 year: 2009 ident: 10.1136/ard.2010.135772_bib25 article-title: Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera publication-title: Arthritis Rheum doi: 10.1002/art.24365 – volume: 107 start-page: 216 year: 1987 ident: 10.1136/ard.2010.135772_bib21 article-title: Primary pulmonary hypertension. A national prospective study publication-title: Ann Intern Med doi: 10.7326/0003-4819-107-2-216 – volume: 103 start-page: 945 year: 1999 ident: 10.1136/ard.2010.135772_bib14 article-title: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor publication-title: J Clin Invest doi: 10.1172/JCI4106 – volume: 354 start-page: 2667 year: 2006 ident: 10.1136/ard.2010.135772_bib23 article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa052955 – volume: 352 start-page: 558 year: 2005 ident: 10.1136/ard.2010.135772_bib13 article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection publication-title: N Engl J Med doi: 10.1056/NEJMoa035717 – volume: 145 start-page: 253 year: 2004 ident: 10.1136/ard.2010.135772_bib32 article-title: Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes publication-title: Endocrinology doi: 10.1210/en.2003-0673 – volume: 50 start-page: 216 year: 2004 ident: 10.1136/ard.2010.135772_bib9 article-title: Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors publication-title: Arthritis Rheum doi: 10.1002/art.11364 – volume: 47 start-page: 731 year: 2007 ident: 10.1136/ard.2010.135772_bib12 article-title: Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.47.120505.105134 – volume: 60 start-page: 907 year: 2009 ident: 10.1136/ard.2010.135772_bib26 article-title: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology publication-title: Arthritis Rheum doi: 10.1002/art.24364 – volume: 19 start-page: 1566 year: 1992 ident: 10.1136/ard.2010.135772_bib10 article-title: Significance of plasma endothelin-1 levels in patients with systemic sclerosis publication-title: J Rheumatol – volume: 49 start-page: 399 year: 2003 ident: 10.1136/ard.2010.135772_bib29 article-title: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies publication-title: Arthritis Rheum doi: 10.1002/art.11113 – reference: 21374902 - Nat Rev Rheumatol. 2011 Feb;7(2):71. doi: 10.1038/nrrheum.2010.218. |
SSID | ssj0000818 |
Score | 2.4826446 |
Snippet | Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated... Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in... BACKGROUND: Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated... |
SourceID | proquest pubmed pascalfrancis crossref istex bmj |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 530 |
SubjectTerms | Adolescent Adult Antibody Specificity Autoantibodies - blood Autoantibodies - immunology Biological and medical sciences Biomarkers - blood Diseases of the osteoarticular system Endothelium, Vascular - immunology Epidemiologic Methods Experiments Female Gene expression Humans Immunoglobulins Immunology Kinases Male Medical sciences Microcirculation - immunology Middle Aged Mortality Patients Prognosis Proteins Raynaud disease Receptor, Angiotensin, Type 1 - immunology Receptor, Endothelin A - immunology Rheumatology Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Scleroderma Scleroderma, Systemic - immunology Studies Thyroid gland Young Adult |
Title | Involvement of functional autoantibodies against vascular receptors in systemic sclerosis |
URI | http://ard.bmj.com/content/70/3/530.full https://api.istex.fr/ark:/67375/NVC-V1ZZD3JS-H/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/21081526 https://www.proquest.com/docview/1777860377 https://www.proquest.com/docview/849429020 https://www.proquest.com/docview/907154792 |
Volume | 70 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZoV0JcEO8ulJUlEOISGsev5ISgtFoqsUJAq6UXy04cFB7J0mQlfj4zcbKrHhbO8SP6xh5_9nyaIeR54vOYuYRFTjIeiVLEkS18GVkF5LzgnsFmR7XFQs3PxdlSLocHt3aQVY4-sXfURZPjG_kR05jpLOZav179jrBqFEZXhxIae2SCqctwVeul3nrilKVjxTyRKT2k9mFcHQH8QdfFuNSYHnjP_fp-7WyaIMx_UCtpW4CrDHUudhPR_kA6vUNuD0ySvgmmv0tu-PoeuflhiJXfJ1_f1-B6-nTgHW1KiidYePijdt01gGjlGtQQUvvNVsAS6ahKpeAF_QrL8NCqpiHXc5XTFqaB_67aB-T89OTL8TwaCimABRLZRSzR1rsMQ6Qud4lCHYzjuQY6J1VqGSucy3QuCpvI3EvpbJm6FLy4Y0p6nvCHZL9uan9AqIhT7QoglZIrwXySOQcNJFzaVOxLKafkGQBpViFVhumvGFwZgNsg3CbAPSWvRqBNPuQix5IYP3d3eLnp8N-xX_SW27SzVz9QvaalWVwcmwt2efmOn3028ymZXTPtpgOwGBhHwEiHo63NsLNbs12HU0I3n2FPYqDF1r5ZtyYVGRzzQMR3N8mA2kmhM5jkUVhF2-kZrFuZqMf_nv4JuRXet1EPd0j2u6u1fwoEqXOzfhfMyOTtyeLjp7-w9w1h |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKwEXxJuFUizxEJe0sRPbyQEh1FLt9rEX2mrpxdiJg8IjWZpdAX-K38hMnOyqh4VTz-tHNDP-_Nn-doaQF9xlIbOcBVawKIiLOAxM7orASCDneeQYLHZUW4zl8DQ-mIjJGvnT_xcGZZU9JrZAndcZ3pHvMIWZzsJIqbfTHwFWjcLX1b6Ehg-LQ_f7JxzZmjejPfDvS87335_sDoOuqgB8DhezgHFlnE3xvdBmlksUhdgoU8BthEwMY7m1qcri3HCROSGsKRKbAKRZJoWLMNEBQP4GbLwhHvbURC2RP2FJX6EvTqXqUgmxSO6Au72OjEVCYTria_b7l0t74Qa69RdqM00D7il8XY3VxLfdAPdvk1sdc6XvfKjdIWuuukuuH3dv8_fIx1EFUNemH5_RuqC4Y_qLRmrmsxo8WNoaNYvUfDYlsFLaq2ApoK6bYtkfWlbU55YuM9rANPDdZXOfnF6JiR-Q9aqu3CNC4zBRNgcSKyIZM8dTa6GBgEOiDF0hxIA8B0PqqU_NodsjTSQ1mFujubU394Bs94bWWZf7HEtwfFvd4fWiw3_HftV6btHOXHxFtZwSeny2q8_Y-fledPBBDwdk65JrFx2ANcE4MYy02ftad0jS6GXcDwhd_AwYgA87pnL1vNFJnAKtAOK_ukkKVFLEKoVJHvooWk7PIG4Fl4__Pf0zcmN4cnykj0bjwyfkpr9bRy3eJlmfXczdUyBnM7vVrghKPl31EvwLEoVIng |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGK028IO50jGGJi3gJjZPYTh4QgnVVu0E1AZu2vRg7cVAGJGVJBfw1fh3n5NJqD4WnPdeX6Nz8HfvrOYQ89WzsMuMxx3DmO0EauI5ObOpoAeA88S0DZ0e2xUxMjoL9E36yQf50_4VBWmUXE-tAnRQx3pEPmcRKZ64v5TBtaRGHo_Hr-Q8HO0jhS2vXTqMxkQP7-yekb-Wr6Qh0_czzxnufdidO22EAPs3jlcM8qa2J8O3QxMYTSBAxfiwB53ARasYSYyIZB4n2eGw5NzoNTQjhzTDBrY9FDyD89yVmRT3Sf7s3O_ywOgdCFnb9-oJIyLawEPPFEJTfsMqYzyUWJ75mvp9fOhn7qORfyNTUJSgrbbpsrIfB9XE4vklutDiWvmkM7xbZsPltsvm-fam_Q06nOQS-uhh5RYuU4vnZXDtSvagK0GdmCmQwUv1FZ4BRaceJpRCD7RybANEsp02l6SymJWwD352Vd8nRlQj5HunlRW4fEBq4oTQJQFrui4BZLzIGBnBIGYVrU84H5AkIUs2bQh2qTnB8oUDcCsWtGnEPyMtO0CpuK6FjQ45v6ye8WE7479rPa80tx-mLr8idk1zNjnfVMTs7G_n7H9VkQHYuqXY5ATAUrBPAStudrlUbV0q18oIBocufISLgM4_ObbEoVRhEADIgDVg_JAJ75YGMYJP7jRWttmdgt9wTW__e_jHZBPdT76azg4fkenPRjsS8bdKrLhb2ESC1yuy0LkHJ56v2wr81RE45 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+functional+autoantibodies+against+vascular+receptors+in+systemic+sclerosis&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Riemekasten%2C+Gabriela&rft.au=Philippe%2C+Aur%C3%A9lie&rft.au=N%C3%A4ther%2C+Melanie&rft.au=Slowinski%2C+Torsten&rft.date=2011-03-01&rft.eissn=1468-2060&rft.volume=70&rft.issue=3&rft.spage=530&rft_id=info:doi/10.1136%2Fard.2010.135772&rft_id=info%3Apmid%2F21081526&rft.externalDocID=21081526 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |